Modafinil effects during acute continuous positive airway pressure withdrawal: A randomized crossover double-blind placebo-controlled trial

Sleep and Circadian Research Group/NHMRC Centre for Sleep Medicine, Woolcock Institute, University of Sydney and Royal Prince Alfred Hospital, Sydney, Australia.
American Journal of Respiratory and Critical Care Medicine (Impact Factor: 13). 04/2010; 181(8):825-31. DOI: 10.1164/rccm.200908-1307OC
Source: PubMed


Continuous positive airway pressure (CPAP) use is associated with reduced motor vehicle accidents in patients with obstructive sleep apnea (OSA). However, interruption of CPAP therapy is common and is associated with a decline in daytime function.
We hypothesized that the wakefulness promoter, modafinil, would ameliorate this decline.
Patients were admitted to the laboratory for three consecutive nights. CPAP was used for the first night, followed by a baseline day, and was then withdrawn for the two subsequent nights (nasal airflow monitored). On each of the mornings after the two CPAP withdrawal nights, patients received 200 mg modafinil or placebo (n = 21) in a randomized, double-blind, crossover design. Treatment periods were separated by a 5-week washout. Driving simulator performance, neurocognitive performance, and subjective alertness were measured by the AusEd driving simulator, psychomotor vigilance task, and Karolinska Sleepiness Scale, respectively.
During CPAP withdrawal, severe sleep-disordered breathing was evident and administration of modafinil improved simulated driving performance (steering variability, P < 0.0001; mean reaction time, P <or= 0.0002; lapses, P <or= 0.01 on a concurrent task), psychomotor vigilance task (mean 1/reaction time and lapses, both P <or= 0.0002), and subjective sleepiness (P <or= 0.01).
Modafinil prevented the decline in simulated driving performance, neurocognitive performance, and subjective sleepiness in patients with OSA with acutely interrupted CPAP therapy. Clinical trial registered with the Australian New Zealand Clinical Trials Registry at (ACTRN12606000027516).

Download full-text


Available from: Nathaniel S Marshall,
  • Source
    • "304 LATSHANG AND BLOCH Theophylline has been shown to improve high altitude periodic breathing in healthy subjects (Fischer et al., 2004) but it is not an effective therapy for OSA and has the drawback of being arrhythmogenic and sleep disturbing. Modafinil is a stimulant that improves reaction time and subjective sleepiness in OSA patients during a few days of CPAP withdrawal (Williams et al., 2010). It might be of some use in very special circumstances when a patient is unable to use an effective OSA therapy but needs to maintain a high level of alertness. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Considering the high prevalence of the obstructive sleep apnea syndrome (OSA), it is expected that many patients with the disorder are traveling to altitude. However, this may expose them to the risk of pronounced hypoxemia, exacerbation of nocturnal breathing disturbances by frequent central apneas, impaired daytime performance, and high blood pressure. Recently, randomized studies specifically investigated the effects of altitude (1630-2590 m) in OSA patients and the optimal treatment in this setting. The results indicate that patients should continue to use continuous positive airway pressure therapy (CPAP) when sleeping at altitude. Since CPAP alone does not control central sleep apnea emerging at altitude, combined treatment with acetazolamide and CPAP should be considered, in particular, in patients with severe OSA and co-morbidities. Supplemental oxygen combined with CPAP might be advantageous in patients with OSA and concomitant cardiopulmonary disease by preventing hypoxemia and central sleep apnea. In patients unable to use CPAP or if electrical power is not available, an optimally fitted mandibular advancement device might be an alternative treatment option that can be combined with acetazolamide during altitude sojourns. Acetazolamide alone is also beneficial and better than no treatment at all, since it improves oxygen saturation, breathing disturbances, and the excessive blood pressure elevation in OSA patients traveling to altitude.
    High altitude medicine & biology 12/2011; 12(4):303-7. DOI:10.1089/ham.2011.1055 · 1.28 Impact Factor
  • Source
    • "Effects of pre-morbid intelligence compared PAP treatment to PAP treatment with an add-on medication with stimulants, to reduce residual sleepiness after PAP treatment, which is a known clinical problem in a subgroup of SRBD patients (Bittencourt et al., 2008; Hirshkowitz et al., 2007; Kingshott et al., 2001; Roth et al., 2006, 2008; Williams et al., 2008, 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Sleep disorders are frequently associated with impaired performance although the type and extent of cognitive deficits varies widely between different types of sleep disorders. Treatment is expected to ameliorate these deficits. However, cognitive functioning and its change with treatment depend on numerous factors. In this chapter we discuss methodological issues, including test selection, and person-specific, task-specific and environmental factors that influence cognitive functioning. In addition, features of study design and sampling strategies are discussed. The chapter ends with a short overview of routes by which treatment may affect cognition in sleep-disordered patients.
    Progress in brain research 01/2010; 185:69-90. DOI:10.1016/B978-0-444-53702-7.00005-1 · 2.83 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with obstructive sleep apnea/hypopnea syndrome can experience residual daytime sleepiness despite regular use of nasal continuous positive airway pressure therapy. This randomized, double-blind, placebo-controlled, parallel group study assessed the efficacy and safety of modafinil for the treatment of residual daytime sleepiness in such patients. Patients received modafinil (n = 77) (200 mg/d, Week 1; 400 mg/d, Weeks 2 to 4) or matching placebo (n = 80) once daily for 4 wk. Modafinil significantly improved daytime sleepiness, with significantly greater mean changes from baseline in Epworth Sleepiness Scale scores at Weeks 1 and 4 (p < 0.001) and in multiple sleep latency times (MSLT) at Week 4 (p < 0.05). The percentage of patients with normalized daytime sleepiness (Epworth score < 10) was significantly higher with modafinil (51%) than with placebo (27%) (p < 0.01), but not for MSLT (> 10 min; 29% versus 25%). Headache (modafinil, 23%; placebo, 11%; p = 0.044) and nervousness (modafinil, 12%; placebo, 3%; p = 0.024) were the most common adverse events. During modafinil or placebo treatment, the mean duration of nCPAP use was 6.2 h/night, with no significant change from baseline observed between groups. Modafinil may be a useful adjunct treatment for the management of residual daytime sleepiness in patients with obstructive sleep apnea/hypopnea syndrome who are regular users of nasal continuous positive airway pressure therapy.
    American Journal of Respiratory and Critical Care Medicine 11/2001; 164(9):1675-81. DOI:10.1164/ajrccm.164.9.2103032 · 13.00 Impact Factor
Show more